Recruiting
Phase 1
Phase 2

Photodynamic Therapy

Sponsor:

Roswell Park Cancer Institute

Code:

NCT06306638

Conditions

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Endobronchial Ultrasound Bronchoscopy

Interstitial Photodynamic Therapy

Palliative Radiation Therapy

Study Details

Brief summary:

This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the patient at a higher risk for respiratory failure, post-obstructive pneumonia, and prolonged hospitalizations. Treatment for these patients may include bronchoscopic intervention (such as mechanical removal, stenting, laser cauterization, or ballooning), radiation therapy with and without chemotherapy. While palliative x-ray radiotherapy may help in shrinking the tumor, high dose curative radiotherapy that can ablate (a localized, nonsurgical destruction) the tumor also has high risk to cause significant toxicity, including bleeding, abnormal connections or passageways between organs or vessels and abnormal scar tissue that can also produce airway obstruction. Photodynamic therapy (PDT) is another possible treatment that can provide local control of the tumor. PDT consists of injecting a light sensitive drug (photosensitizer, PS) into the vein, waiting for the PS to accumulate in the tumor, and then activating it with a red laser light. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving interstitial photodynamic therapy following palliative radiotherapy may improve tumor response and survival without the serious side effects that are associated with the typical high dose curative x-ray radiotherapy alone in patients with malignant central airway obstruction.

Conditions

Malignant Solid Neoplasm

Study ID

NCT06306638

Start date

Oct 1, 2024

Status verified date

Mar, 2026

Completion date

Oct 1, 2029

Anticipated

Primary completion date

Oct 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age >= 18 years of age
  • Eligibility checklist before registration requires review of case by the interventional pulmonologist/s and radiation oncologist/s to approve anatomic feasibility of an airway intervention and palliative radiotherapy
  • Patients with pathologic diagnosis of inoperable solid malignancy involving extrabronchial tumor growth that causes airway obstruction and not amenable to curative radiotherapy. All patients will have tumors requiring bronchoscopic intervention with endobronchial ultrasound (EBUS) at the time of I-PDT
  • Participants have at least one measurable lesion which is also the target lesion for Response Evaluation Criteria in Solid Tumors (RECIST) measurement
  • Patients amenable to receive standard of care palliative radiotherapy to the target tumor, as determined by the radiation oncologist/s
  • Amenable to high resolution chest CT (with or without contrast due to contraindication) with 0.625-1.25 mm slice thickness and slice interval 0.5-1 mm
  • Tumor is accessible and amenable to I-PDT, as determined by the interventional pulmonologist/s
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3
  • Platelets ≥ 100,000 cells/mm\^3 (International System of Units \[SI\] units 100 x 10\^9/L)
  • International normalized ratio (INR) < 1.5 and activated partial thromboplastin time (aPTT) < 1.5 x ULN. PTT or aPTT per institutional standards for participating external sites
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 3 months after receiving the study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Pregnant or nursing female participants
  • Co-existing ophthalmic disease likely to require slit-lamp examination within the next 30 days following I-PDT treatment
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the I-PDT
  • CT imaging suggestive of target tumor invasion into a major blood vessel (typically proximal to segmental vessels)
  • Known hypersensitivity/allergy to porphyrin
  • Patients who are not cleared by the anesthesiologist to undergo an advanced bronchoscopy procedure under general anesthesia
  • Patients diagnosed with porphyria
  • Patients with known allergy to eggs
  • Patients unwilling or unable to follow protocol requirements

Study Design

Enrollment

42 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase I cohort 1 (I-PDT, EBUS)

Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

experimental: Phase I cohort 2 (I-PDT, EBUS, palliative radiation therapy)

Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

experimental: Phase II (I-PDT, EBUS, palliative radiation therapy)

Phase II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

Interventions

Biospecimen Collection

Undergo blood and tissue sample collection

Computed Tomography

Undergo CT

Endobronchial Ultrasound Bronchoscopy

Undergo EBUS

Interstitial Photodynamic Therapy

Undergo I-PDT

Palliative Radiation Therapy

Undergo palliative radiation therapy

Physical Performance Testing

Ancillary studies

Questionnaire Administration

Ancillary studies

Verteporfin

Given IV

Laser: ML7710-PDT

Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.

Primary outcome measure

  • Incidence of >= grade 3 adverse events (Phase I) [ Time Frame: Within 30 days post interstitial photodynamic therapy (I-PDT) ]
  • Overall tumor response (Phase II) [ Time Frame: At 12 weeks post I-PDT ]

Central Contacts and Locations

Central contacts

ASKRPCI@RoswellPark.org

1-877-275-7724askrpci@roswellpark.org

Locations

Roswell Park Cancer Institute

Recruiting

Buffalo, New York, United States, 14263

Contacts

Nathaniel Ivanick

716-845-5873Nathaniel.Ivanick@RoswellPark.org

Principal Investigator:

Nathaniel Ivanick

Abramson Cancer Center

Recruiting

Philadelphia, Pennsylvania, United States, 19104

More Information

Sponsor

Roswell Park Cancer Institute

Last update posted

Apr 6, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Roswell Park Cancer Institute on 2026-04-06.